UPDATED SAFETY AND QUALITY OF LIFE (QOL) RESULTS OF PARAMOUNT STUDY: MAINTENANCE PEMETREXED (PEM) PLUS BEST SUPPORTIVE CARE (BSC) VS PLACEBO (PBO) PLUS BSC IMMEDIATELY FOLLOWING INDUCTION TREATMENT WITH PEM PLUS CISPLATIN (CP) FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NS-NSCLC)

被引：0
|
作者：
Pujol, J. [1 ]
Paz-Ares, L. [2 ]
Dediu, M. [3 ]
Thomas, M. [4 ]
Bidoli, P. [5 ]
Corral, J. [2 ]
Chouaki, N. [6 ]
Visseren-Grul, C. M. [7 ]
Zimmermann, A. [8 ]
Gridelli, C. [9 ]
机构：
[1] Hosp Arnaud de Villeneuve, Montpellier Acad Hosp, Thorac Oncol Unit, Montpellier, France
[2] Hosp Univ Virgen del Rocio, Seville, Spain
[3] Fundeni Clin Hosp Alexandru Treistoreanu, Inst Oncol Bucharest, Bucharest, Romania
[4] Univ Heidelberg, Thoraxklin Heidelberg, Dept Thorac Oncol, D-6900 Heidelberg, Germany
[5] Azienda Osped S Gerardo UO Oncol Med, Monza, Italy
[6] Eli Lilly & Co, Dept Med, Paris, France
[7] Eli Lilly & Co, Oncol Europe, Ra Houten, Netherlands
[8] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA
[9] UO Oncol Med SG Moscati Hosp, Avellino, Italy
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：418 / 419
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials
    Scagliotti, G. V.
    Gridelli, C.
    de Marinis, F.
    Thomas, M.
    Dediu, M.
    Pujol, J. -L.
    Manegold, C.
    San Antonio, B.
    Peterson, P. M.
    John, W.
    Chouaki, N.
    Visseren-Grul, C.
    Paz-Ares, L. G.
    [J]. LUNG CANCER, 2014, 85 (03) : 408 - 414
  • [42] ISEL: a Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens
    Thatcher, N
    Chang, A
    Parikh, P
    Pemberton, K
    Archer, V
    [J]. LUNG CANCER, 2005, 49 : S4 - S4
  • [43] A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
    Nabil Mubarak
    Rabab Gaafar
    Samir Shehata
    Tarek Hashem
    Dani Abigeres
    Hamdy A Azim
    Gamal El-Husseiny
    Hamed Al-Husaini
    Zhixin Liu
    [J]. BMC Cancer, 12
  • [44] A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
    Mubarak, Nabil
    Gaafar, Rabab
    Shehata, Samir
    Hashem, Tarek
    Abigeres, Dani
    Azim, Hamdy A.
    El-Husseiny, Gamal
    Al-Husaini, Hamed
    Liu, Zhixin
    [J]. BMC CANCER, 2012, 12
  • [45] PALLIATIVE RADIATION DURING PEMETREXED PLUS CISPLATIN FIRST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PATIENT SAFETY IN THE JMDB AND PARAMOUNT TRIALS
    Scagliotti, G. V.
    Gridelli, C.
    de Marinis, F.
    Biesma, B.
    Reck, M.
    San Antonio, B.
    Zimmermann, A. H.
    Visseren-Grul, C.
    Chouaki, N.
    Paz-Ares, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S45 - S45
  • [46] Final overall survival (OS) results from a phase II study of pemetrexed (Pem) and cisplatin (Cis) with concurrent thoracic radiation (RT) after Pem-Cis induction in patients with unresectable locally advanced (LA) nonsquamous non-small cell lung cancer (NS-NSCLC).
    Novello, Silvia
    Engel-Riedel, Walburga
    Serke, Monika
    Giraud, Philippe
    Visseren-Grul, Carla
    Ameryckx, Sophie
    Soldatenkova, Victoria
    Chouaki, Nadia
    Garrido, Pilar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Oral vinorelbine (NVBo) plus cisplatin (CDDP) versus pemetrexed (PEM) plus CDDP followed by maintenance with single agent NVBo or PEM as first-line treatment of patients (pts) with advanced non-squamous non small cell lung cancer (NS-NSCLC): A cost minimization analysis from the Italian National Health System (NHS) perspective
    Favaretto, A.
    Ciuffreda, L.
    Nicolini, M.
    Camerini, A.
    Melotti, B.
    Berardi, R.
    Mencoboni, M.
    Lucioni, C.
    Mazzi, S.
    Bennouna, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S329 - S329
  • [48] GILT study: Oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): Final results of a phase (ph) III study
    Huber, Rudolf M.
    Engel-Riedel, Walburga
    Kollmeier, Jens
    Andreas, Stefan
    Staar, Susanne
    Klautke, Gunther
    Fietkau, Rainer
    Vaissiere, Nathalie
    Osowski, Susanne
    Flentje, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] EFFICACY AND SAFETY OF MAINTENANCE PEMETREXED IN PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) AFTER COMPLETING AT LEAST 4 CYCLES OF PEMETREXED PLUS CISPLATIN INDUCTION TREATMENT: A CROSS-TRIAL ANALYSIS OF TWO PHASE III TRIALS
    Scagliotti, Giorgio V.
    Gridelli, Cesare
    De Marinis, Filippo
    Thomas, Michael
    Dediu, Mircea
    Pujol, Jean-Lois
    Manegold, Christian
    San Antonio, Belen
    Peterson, Patrick M.
    John, William J.
    Chouaki, Nadia
    Visseren-Grul, Carla
    Paz-Ares, Luis G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S877 - S878
  • [50] Randomized, open-label, phase III study of pemetrexed plus carboplatin followed by maintenance pemetrexed (Arm A) versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab (Arm B) in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).
    Zinner, Ralph
    Ross, Helen J.
    Weaver, Robert
    Govindan, Ramaswamy
    Holden, Viran R.
    Chowhan, Naveed Mahfooz
    Beck, J. Thaddeus
    Waterhouse, David Michael
    Modiano, Manuel
    Rao, Vijay Phooshkooru
    Liu, Jingyi
    Koustenis, Andrew
    Melemed, Symantha
    Guba, Susan C.
    Ortuzar, Waldo Feliu
    Desaiah, Durisala
    Spigel, David R.
    Obasaju, Coleman K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345